- South Korea
- /
- Medical Equipment
- /
- KOSDAQ:A376930
NoulLtd Full Year 2024 Earnings: ₩608 loss per share (vs ₩609 loss in FY 2023)
NoulLtd (KOSDAQ:376930) Full Year 2024 Results
Key Financial Results
- Net loss: ₩22.5b (loss widened by 38% from FY 2023).
- ₩608 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
NoulLtd shares are up 9.6% from a week ago.
Risk Analysis
We should say that we've discovered 5 warning signs for NoulLtd (2 are a bit unpleasant!) that you should be aware of before investing here.
If you're looking to trade NoulLtd, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentValuation is complex, but we're here to simplify it.
Discover if NoulLtd might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSDAQ:A376930
NoulLtd
Engages in the in vitro diagnosis and remote diagnosis business worldwide.
Excellent balance sheet moderate.